SIDE-BY-SIDE EVIDENCE
Compare evidence.
Keep the context.
Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.
Choose profilesSIDE-BY-SIDE EVIDENCE VIEW
Compare selected profiles
| Molecule |  Ivermectin | Prednisone |  LL-37 |
|---|---|---|---|
| Research Topic | Clinical / Endocrine Pharmacology | Clinical / Endocrine Pharmacology | Tissue / Repair Research |
| Pharmacology | Antiparasitic medicine with human and veterinary products that are not interchangeable | Systemic glucocorticoid prodrug medicine | Cathelicidin host-defence peptide |
| PrimeCore Class | Class AApproved in a bounded context | Class AApproved in a bounded context | Class BInvestigational |
| Evidence Grade | Grade AStrong regulatory + clinical evidence | Grade AStrong regulatory + clinical evidence | Grade CEarly human evidence |
| Evidence boundary | Ivermectin is classified here as Antiparasitic medicine with human and veterinary products that are not interchangeable. Strong evidence and labels support specific parasitic infections, not unrelated conditions or veterinary formulations in humans. FDA-authorised human prescription products exist for defined parasitic infections; veterinary products and unapproved indications are separate. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions. | Prednisone is classified here as Systemic glucocorticoid prodrug medicine. Extensive prescription evidence applies to disease-specific regimens and monitoring, not general recovery or performance use. FDA-authorised prescription products exist; WADA prohibits systemic glucocorticoids in competition by specified routes and requires current rule checking. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions. | LL-37 has investigational topical wound data, not blanket antimicrobial approval. The 148-patient phase IIb trial did not improve healing significantly in the overall cohort; post-hoc large-ulcer signals require confirmation. FDA describes impurity/immunogenicity concerns and nonclinical safety signals. Topical findings do not establish injection safety. |
| Unknowns | Insufficient data in the current dataset | Insufficient data in the current dataset | Insufficient data in the current dataset |
| Limitations |
|
| English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language)
|
| Sources | |||
| Read more | Read English overview | Read English overview | Read English overview |
This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.
Choose another comparisonContinue reading
Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.
10 questions before drawing conclusions